Results 101 to 110 of about 137,029 (384)

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis [PDF]

, 2004
Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA).
Aarden, L., Dijkmans, B.A.C., Groot, E., Lems, W.F., Nurmohamed, M.T., Tak, PP, Voskuijl, A.E., Wolbink, G.J.   +7 more
core   +2 more sources

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.

Gastroenterology, 2016
BACKGROUND & AIMS Little is known about in utero exposure to and postnatal clearance of anti-tumor necrosis factor (anti-TNF) agents in neonates. We investigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and ...
M. Julsgaard, L. Christensen, P. Gibson, R. Gearry, J. Fallingborg, C. Hvas, B. Bibby, N. Uldbjerg, W. Connell, O. Rosella, A. Grosen, Steven J Brown, J. Kjeldsen, S. Wildt, L. Svenningsen, M. Sparrow, A. Walsh, S. Connor, G. Radford-Smith, I. Lawrance, J. Andrews, Kathrine Ellard, S. Bell   +22 more
semanticscholar   +1 more source

Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. [PDF]

, 2019
BackgroundCoronary artery aneurysms (CAA) are a serious complication of Kawasaki disease. Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the risk of CAA from 25% to <5%.
Baker, Annette L, Burns, Jane C, Dahdah, Nagib, de Ferranti, Sarah D, Dionne, Audrey, Fournier, Anne, Friedman, Kevin G, Gauvreau, Kimberlee, Gould, Patrick, Newburger, Jane W, Son, Mary Beth, Tremoulet, Adriana H   +11 more
core  

Genome Wide Transcriptome Analysis of Dendritic Cells Identifies Genes with Altered Expression in Psoriasis [PDF]

, 2013
Activation of dendritic cells by different pathogens induces the secretion of proinflammatory mediators resulting in local inflammation. Importantly, innate immunity must be properly controlled, as its continuous activation leads to the development of ...
Filkor, Katalin, Hegedűs, Zoltán, Kemény, Lajos, Kondorosi, Éva, Nagy, István, Szász, András, Tubák, Vilmos   +6 more
core   +3 more sources

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Gastroenterology, 2016
BACKGROUND & AIMS Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence.
M. Regueiro, B. Feagan, B. Zou, J. Johanns, M. Blank, M. Chevrier, S. Plevy, J. Popp, F. Cornillie, M. Lukáš, S. Danese, P. Gionchetti, S. Hanauer, W. Reinisch, W. Sandborn, D. Sorrentino, P. Rutgeerts   +16 more
semanticscholar   +1 more source

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

Arthritis &Rheumatology, EarlyView.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino, Maria Vittoria Cicinelli, Elisabetta Miserocchi, Stefania Costi, Francesco Baldo, Maurizio Virgilio Gattinara, Pierluigi Scandale, Scott D. Smith, Debra A. Goldstein, Dina Baddar, Terese K. A. Gerges, Timothy M. Janetos, Matilde Ruiz‐Cruz, Kazuichi Maruyama, Massimiliano Serafino, Paola Camicione, Vishali Gupta, Radgonde Amer, Emilio M. Dodds, Sebastian Inchauspe, Marion R. Munk, Ester Carreño, Soon‐Phaik Chee, Aniruddha Agarwal, Ariel Schlaen, Ramiro A. Gómez, Cristobal A. Couto, Moncef Khairallah, Piergiorgio Neri, Cecilia B. Chighizola, Roberto F. Caporali, Francesco Pichi   +31 more
wiley   +1 more source

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. [PDF]

, 2019
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX ...
DeHoratius, Raphael J., Ellis, Lorie A., Kafka, Shelly, Kubacki, Maureen, Malangone-Monaco, Elisabetta, Stetsovsky, Diana, Varker, Helen   +6 more
core   +1 more source

The nocebo effect challenges the non-medical infliximab switch in practice

European Journal of Clinical Pharmacology, 2018
In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits.
N. Boone, L. Liu, M. Romberg-Camps, L. Duijsens, C. Houwen, P. Kuy, R. Janknegt, R. Peeters, R. Landewé, B. Winkens, A. Bodegraven   +10 more
semanticscholar   +1 more source

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E. McGuire, Patrick Gillespie, Laurence J. Egan   +7 more
wiley   +1 more source